Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2100
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMoon, Daniel-
dc.contributor.authorMurphy, Declan-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorBolton, Damian-
dc.contributor.otherTrigos, Anna-
dc.contributor.otherPasam, Anupama-
dc.contributor.otherBanks, Patricia-
dc.contributor.otherWallace, Roslyn-
dc.contributor.otherGuo, Christina-
dc.contributor.otherKeam, Simon-
dc.contributor.otherThorne, Heather-
dc.contributor.otherkConFab, Catherine-
dc.contributor.otherLade, Stephen-
dc.contributor.otherClouston, David-
dc.contributor.otherHakansson, Alexander-
dc.contributor.otherLiu, Yang-
dc.contributor.otherBlyth, Benjamin-
dc.contributor.otherDarcy, Phil-
dc.contributor.otherHaupt, Ygal-
dc.contributor.otherWilliams, Scott-
dc.contributor.otherCastro, Elena-
dc.contributor.otherOlmos, David-
dc.contributor.otherGoode, David-
dc.contributor.otherNeeson, Paul-
dc.contributor.otherShahneen, Sandhu-
dc.date.accessioned2022-07-05T05:32:06Z-
dc.date.available2022-07-05T05:32:06Z-
dc.date.issued2022-06-
dc.identifier.citationJ Immunother Cancer . 2022 Jun;10(6):e003744en_US
dc.identifier.issn2051-1426en_US
dc.identifier.urihttp://hdl.handle.net/11434/2100-
dc.description.abstractBackground: Aberrations in homologous recombination repair (HRR) genes are emerging as important biomarkers for personalized treatment in prostate cancer (PCa). HRR deficiency (HRD) could affect the tumor immune microenvironment (TIME), potentially contributing to differential responses to poly ADP-ribose polymerase (PARP) inhibitors and immune checkpoint inhibitors. Spatial distribution of immune cells in a range of cancers identifies novel disease subtypes and is related to prognosis. In this study we aimed to determine the differences in the TIME of PCa with and without germline (g) HRR mutations. Methods: We performed gene expression analysis, multiplex immunohistochemistry of T and B cells and quantitative spatial analysis of PCa samples from 36 patients with gHRD and 26 patients with sporadic PCa. Samples were archival tumor tissue from radical prostatectomies with the exception of one biopsy. Results were validated in several independent cohorts. Results: Although the composition of the T cell and B cells was similar in the tumor areas of gHRD-mutated and sporadic tumors, the spatial profiles differed between these cohorts. We describe two T-cell spatial profiles across primary PCa, a clustered immune spatial (CIS) profile characterized by dense clusters of CD4+ T cells closely interacting with PD-L1+ cells, and a free immune spatial (FIS) profile of CD8+ cells in close proximity to tumor cells. gHRD tumors had a more T-cell inflamed microenvironment than sporadic tumors. The CIS profile was mainly observed in sporadic tumors, whereas a FIS profile was enriched in gHRD tumors. A FIS profile was associated with lower Gleason scores, smaller tumors and longer time to biochemical recurrence and metastasis. Conclusions: gHRD-mutated tumors have a distinct immune microenvironment compared with sporadic tumors. Spatial profiling of T-cells provides additional information beyond T-cell density and is associated with time to biochemical recurrence, time to metastasis, tumor size and Gleason scores.en_US
dc.publisherBMJen_US
dc.subjectGene Expression Profilingen_US
dc.subjectGenetic Markersen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectProstate Canceren_US
dc.subjectTumor Microenvironmenten_US
dc.subjectHomologous Recombination Repairen_US
dc.subjectHRRen_US
dc.subjectHomologous Recombination Repair Deficiencyen_US
dc.subjectHRDen_US
dc.subjectTumor Immune Microenvironmenten_US
dc.subjectTIMEen_US
dc.subjectPoly ADP-Ribose Polymeraseen_US
dc.subjectPARPen_US
dc.subjectGermlineen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.subjectEpworth Prostate Centre, Epworth HealthCare, Victoria, Australiaen_US
dc.titleTumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1136/jitc-2021-003744en_US
dc.identifier.journaltitleJournal of ImmunoTherapy of Canceren_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35764368/en_US
dc.description.affiliatesDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.en_US
dc.description.affiliatesInstitute of Cancer Research Sutton, Sutton, Surrey, UK.en_US
dc.description.affiliatesRoyal Marsden Hospital Sutton, Sutton, London, UK.en_US
dc.description.affiliatesDepartment of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.description.affiliatesTissuPath, Melbourne, Victoria, Australia.en_US
dc.description.affiliatesVeracyte Inc, South San Francisco, California, USAen_US
dc.description.affiliatesDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.description.affiliatesAustin Hospital, Heidelberg, Victoria, Australia.en_US
dc.description.affiliatesDivision of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.description.affiliatesInstituto de Investigacion Biomedica de Malaga, Malaga, Spainen_US
dc.description.affiliatesMedical Oncology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.en_US
dc.description.affiliatesDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.type.studyortrialRetrospective studiesen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services
Epworth Prostate Centre

Files in This Item:
File Description SizeFormat  
moon.pdf7.85 MBAdobe PDFThumbnail
View/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.